<DOC>
	<DOCNO>NCT02559492</DOCNO>
	<brief_summary>This open-label , Phase 1b , platform study subject advance metastatic solid tumor . The study divide 2 part ( Part 1a Part 1b ) . Part 1a evaluate JAK inhibitor JAK1 selectivity ( INCB039110 ) combination IDO1 inhibitor ( epacadostat ; INCB024360 ; Group A ) INCB039110 combination PI3K-delta inhibitor ( INCB050465 ; Group B ) determine MTD PAD recommend Part 1b dose combination . Once recommend dose identified treatment group Part 1a , subject advance solid tumor enrol expansion cohort base upon prior treatment history PD-1 pathway-targeted agent ( Part 1b ) .</brief_summary>
	<brief_title>INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Male female , age 18 year old . Willingness provide write informed consent study . Part 1a : Subjects histologically cytologically confirm advanced metastatic solid tumor fail prior standard therapy ( include subject refusal intolerance ) . Part 1b : Subjects endometrial cancer , gastric cancer , head neck squamous cell carcinoma , melanoma , microsatellite unstable colorectal cancer , nonsmall cell lung cancer , pancreatic ductal adenocarcinoma , renal cell carcinoma , triple negative breast cancer , transitional cell carcinoma genitourinary tract disease progression available therapy metastatic disease know confer clinical benefit , intolerant treatment , refuse standard treatment . Part 1b : Must document confirmed disease progression prior program cell death1 ( PD1 ) pathway targeted agent must PD1 pathwaytargeted treatment na√Øve . Has baseline tumor biopsy specimen available willingness undergo pretreatment tumor biopsy obtain specimen . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Laboratory parameter within protocoldefined range . Receipt anticancer medication investigational drug within define interval first administration study drug . Received immunesuppressive base treatment reason within 14 day prior first dose study treatment . Has recover toxic effect prior therapy &lt; Grade 1 . Active inactive autoimmune process . Has receive live vaccine within 30 day plan start study therapy . Active infection require systemic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>